Another pharma major considers exiting generics in the USA

Switzerland’s Novartis (NOVN: VX) is mulling a sale of its generic dermatologics business, which primarily does business in the USA, according to Reuters.

The unit, which could be worth as much as $1.6 billion, comprises a number of skin-care treatments and particular manufacturing facilities.

While the firm’s generics subsidiary Sandoz has fared well producing complex generics such as  injectables and inhalables, its in-house copycat unit has not been as profitable, and the Basel-based pharmaceuticals giant is reportedly planning to refocus its efforts on its cancer business.